242 related articles for article (PubMed ID: 24285017)
1. Antibody-based immunotherapy for ovarian cancer: where are we at?
Tse BW; Collins A; Oehler MK; Zippelius A; Heinzelmann-Schwarz VA
Ann Oncol; 2014 Feb; 25(2):322-31. PubMed ID: 24285017
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab.
Berek JS
Expert Opin Biol Ther; 2004 Jul; 4(7):1159-65. PubMed ID: 15268682
[TBL] [Abstract][Full Text] [Related]
3. A robust immune system conditions the response to abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination in ovarian cancer patients.
Battaglia A; Fossati M; Buzzonetti A; Scambia G; Fattorossi A
Immunol Lett; 2017 Nov; 191():35-39. PubMed ID: 28919454
[TBL] [Abstract][Full Text] [Related]
4. Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.
Grisham RN; Berek J; Pfisterer J; Sabbatini P
Immunotherapy; 2011 Feb; 3(2):153-62. PubMed ID: 21322756
[TBL] [Abstract][Full Text] [Related]
5. Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13.
Drugs R D; 2006; 7(6):379-83. PubMed ID: 17073521
[TBL] [Abstract][Full Text] [Related]
6. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
Seimetz D; Lindhofer H; Bokemeyer C
Cancer Treat Rev; 2010 Oct; 36(6):458-67. PubMed ID: 20347527
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal Antibodies.
Geskin LJ
Dermatol Clin; 2015 Oct; 33(4):777-86. PubMed ID: 26433849
[TBL] [Abstract][Full Text] [Related]
8. Anti-idiotypic antibody abagovomab in advanced ovarian cancer.
Bauerschlag DO; Schem C; Baumann K; Harter P; Hilpert F; Wagner U; du Bois A; Pfisterer J
Future Oncol; 2008 Dec; 4(6):769-73. PubMed ID: 19086842
[TBL] [Abstract][Full Text] [Related]
9. Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer.
Shen J; Zhu Z
Curr Opin Mol Ther; 2008 Jun; 10(3):273-84. PubMed ID: 18535935
[TBL] [Abstract][Full Text] [Related]
10. Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial.
Buzzonetti A; Fossati M; Catzola V; Scambia G; Fattorossi A; Battaglia A
Cancer Immunol Immunother; 2014 Oct; 63(10):1037-45. PubMed ID: 24952307
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive T-cell antibody induction for heart transplant recipients.
Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
[TBL] [Abstract][Full Text] [Related]
12. [Progression of immunotherapy in gastric cancer].
Wei X; Xu R
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Feb; 19(2):225-32. PubMed ID: 26831889
[TBL] [Abstract][Full Text] [Related]
13. IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer.
Thibodeaux SR; Barnett BB; Pandeswara S; Wall SR; Hurez V; Dao V; Sun L; Daniel BJ; Brumlik MJ; Drerup J; Padrón Á; Whiteside T; Kryczek I; Zou W; Curiel TJ
Clin Cancer Res; 2021 Jul; 27(13):3661-3673. PubMed ID: 33771857
[TBL] [Abstract][Full Text] [Related]
14. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
Van Gelder T; Warlé M; Ter Meulen RG
Drugs; 2004; 64(16):1737-41. PubMed ID: 15301558
[TBL] [Abstract][Full Text] [Related]
15. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
16. Oregovomab: an investigational agent for the treatment of advanced ovarian cancer.
Pietragalla A; Duranti S; Daniele G; Nero C; Ciccarone F; Lorusso D; Fagotti A; Scambia G
Expert Opin Investig Drugs; 2021 Feb; 30(2):103-110. PubMed ID: 33423551
[No Abstract] [Full Text] [Related]
17. New monoclonal antibodies for hematologic malignancies (and breast cancer).
Curtis MA
Med Health R I; 2003 Aug; 86(8):256-7. PubMed ID: 14582224
[No Abstract] [Full Text] [Related]
18. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.
de Vries IJ; Castelli C; Huygens C; Jacobs JF; Stockis J; Schuler-Thurner B; Adema GJ; Punt CJ; Rivoltini L; Schuler G; Coulie PG; Lucas S
Clin Cancer Res; 2011 Feb; 17(4):841-8. PubMed ID: 21177412
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
20. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM; Method M
J Immunother; 2009 Jan; 32(1):54-65. PubMed ID: 19307994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
